---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-088662"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2026-07-30T20:03:20+00:00"
generated_at: "2026-07-30T20:04:08.334233+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Yarrow Bioscience exchanges shares for pre-funded warrants; warrant count dwarfs common shares

## Summary
- Exchanged 133,290 common shares for pre-funded warrants to purchase same number at $0.0001/share.
- After exchange: 2,669,788 common shares outstanding; 25,914,530 pre-funded warrants outstanding.
- Warrants immediately exercisable, subject to 9.99% beneficial ownership limitation (can be increased to 19.99%).
- Exchange closed July 29, 2026; issued under Section 3(a)(9) exemption from registration.

## SEC filing metadata
- accession: 0001104659-26-088662
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2026-07-30T20:03:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465926088662/0001104659-26-088662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465926088662/tm2621655d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-088662
- JSON: https://secwatch.observer/filing/0001104659-26-088662.json
- Plain text: https://secwatch.observer/filing/0001104659-26-088662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.